Candriam SCA’s Vir Biotechnology VIR Stock Holding History

Candriam SCA’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10.2M	Buy	1,135,763 +104,100	+10%	+$829K	0.05%	280
2025 Q4	$6.22M	Buy	+1,031,663	New	+$6.14M	0.03%	348
2023 Q4	–	Sell	-11,026	Closed	–	–	727
2023 Q3	$0	Sell	11,026 -343,619	-97%	-$4.9M	﹤0.01%	693
2023 Q2	$8.7M	Buy	+354,645	New	+$8.91M	0.06%	263
2021 Q2	–	Sell	-226,238	Closed	-$5.82M	–	943
2021 Q1	$5.82M	Hold	226,238	–	–	0.05%	347
2020 Q4	$6.06M	Buy	226,238 +20,616	+10%	+$670K	0.05%	356
2020 Q3	$7.06M	Buy	+205,622	New	+$8.85M	0.07%	292

Other funds holding VIR

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

GSK plc London $599M AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Goldman Sachs New York $761B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ADAR1 Capital Management Austin, Texas $1.66B AUM 340.85% 1-Year Est. Return